194 related articles for article (PubMed ID: 27768831)
1. Repair of Bone Erosion in Rheumatoid Arthritis by Denosumab: A High-Resolution Peripheral Quantitative Computed Tomography Study.
Yue J; Griffith JF; Xiao F; Shi L; Wang D; Shen J; Wong P; Li EK; Li M; Li TK; Zhu TY; Hung VW; Qin L; Tam LS
Arthritis Care Res (Hoboken); 2017 Aug; 69(8):1156-1163. PubMed ID: 27768831
[TBL] [Abstract][Full Text] [Related]
2. Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial.
Takeuchi T; Tanaka Y; Ishiguro N; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D
Ann Rheum Dis; 2016 Jun; 75(6):983-90. PubMed ID: 26585988
[TBL] [Abstract][Full Text] [Related]
3. Comparative study of the inhibitory effect on bone erosion progression with denosumab treatment and conventional treatment in rheumatoid arthritis patients: study protocol for an open-label randomized controlled trial by HR-pQCT.
Iwamoto N; Sato S; Sumiyoshi R; Chiba K; Miyamoto N; Arinaga K; Kobayashi M; Yamamoto H; Osaki M; Kawakami A
Trials; 2019 Aug; 20(1):494. PubMed ID: 31409388
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.
Iwamoto N; Chiba K; Sato S; Shiraishi K; Watanabe K; Oki N; Okada A; Koga T; Kawashiri SY; Tamai M; Hosogaya N; Furuyama M; Kobayashi M; Saito K; Okubo N; Uetani M; Osaki M; Kawakami A
Arthritis Res Ther; 2022 Dec; 24(1):264. PubMed ID: 36476479
[TBL] [Abstract][Full Text] [Related]
5. Assessment of 3-month changes in bone microstructure under anti-TNFα therapy in patients with rheumatoid arthritis using high-resolution peripheral quantitative computed tomography (HR-pQCT).
Shimizu T; Choi HJ; Heilmeier U; Tanaka M; Burghardt AJ; Gong J; Chanchek N; Link TM; Graf J; Imboden JB; Li X
Arthritis Res Ther; 2017 Oct; 19(1):222. PubMed ID: 28978352
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of denosumab with regard to bone destruction in prognostic subgroups of Japanese rheumatoid arthritis patients from the phase II DRIVE study.
Ishiguro N; Tanaka Y; Yamanaka H; Yoneda T; Ohira T; Okubo N; Genant HK; van der Heijde D; Takeuchi T
Rheumatology (Oxford); 2019 Jun; 58(6):997-1005. PubMed ID: 30602032
[TBL] [Abstract][Full Text] [Related]
7. Effect of treat-to-target strategies on bone erosion progression in early rheumatoid arthritis: An HR-pQCT study.
Yue J; Griffith JF; Xu J; Xiao F; Shi L; Wang D; Wong PCH; Li EK; Li M; Li TK; Mak WY; Zhu TY; Hung VW; Qin L; Tam LS
Semin Arthritis Rheum; 2018 Dec; 48(3):374-383. PubMed ID: 29858113
[TBL] [Abstract][Full Text] [Related]
8. Effects of RANKL inhibition on promoting healing of bone erosion in rheumatoid arthritis using HR-pQCT: a 2-year, randomised, double-blind, placebo-controlled trial.
So H; Cheng IT; Lau SL; Chow E; Lam T; Hung VW; Li EK; Griffith JF; Lee VW; Shi L; Huang J; Kwok KY; Yim CW; Li TK; Lo V; Lee J; Lee JJ; Qin L; Tam LS
Ann Rheum Dis; 2021 Aug; 80(8):981-988. PubMed ID: 33811034
[TBL] [Abstract][Full Text] [Related]
9. Effects of Teriparatide on Joint Erosions in Rheumatoid Arthritis: A Randomized Controlled Trial.
Solomon DH; Kay J; Duryea J; Lu B; Bolster MB; Yood RA; Han R; Ball S; Coleman C; Lo E; Wohlfahrt A; Sury M; Yin M; Yu Z; Zak A; Gravallese EM
Arthritis Rheumatol; 2017 Sep; 69(9):1741-1750. PubMed ID: 28544807
[TBL] [Abstract][Full Text] [Related]
10. Automated three-dimensional registration of high-resolution peripheral quantitative computed tomography data to quantify size and shape changes of arthritic bone erosions.
Töpfer D; Gerner B; Finzel S; Kraus S; Museyko O; Schett G; Engelke K
Rheumatology (Oxford); 2015 Dec; 54(12):2171-80. PubMed ID: 26175467
[TBL] [Abstract][Full Text] [Related]
11. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients.
Deodhar A; Dore RK; Mandel D; Schechtman J; Shergy W; Trapp R; Ory PA; Peterfy CG; Fuerst T; Wang H; Zhou L; Tsuji W; Newmark R
Arthritis Care Res (Hoboken); 2010 Apr; 62(4):569-74. PubMed ID: 20391513
[TBL] [Abstract][Full Text] [Related]
12. Assessment of Distal Radius Bone Mineral Density in Osteoporosis Patients Receiving Denosumab, Including Those with Rheumatoid Arthritis and Those Receiving Oral Glucocorticoids.
Matsuno H
Drugs R D; 2016 Dec; 16(4):347-353. PubMed ID: 27766589
[TBL] [Abstract][Full Text] [Related]
13. Effects of denosumab on the geometry of the proximal femur in postmenopausal women in comparison with alendronate.
Beck TJ; Lewiecki EM; Miller PD; Felsenberg D; Liu Y; Ding B; Libanati C
J Clin Densitom; 2008; 11(3):351-9. PubMed ID: 18495508
[TBL] [Abstract][Full Text] [Related]
14. Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate.
Seeman E; Delmas PD; Hanley DA; Sellmeyer D; Cheung AM; Shane E; Kearns A; Thomas T; Boyd SK; Boutroy S; Bogado C; Majumdar S; Fan M; Libanati C; Zanchetta J
J Bone Miner Res; 2010 Aug; 25(8):1886-94. PubMed ID: 20222106
[TBL] [Abstract][Full Text] [Related]
15. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial.
Cohen SB; Dore RK; Lane NE; Ory PA; Peterfy CG; Sharp JT; van der Heijde D; Zhou L; Tsuji W; Newmark R;
Arthritis Rheum; 2008 May; 58(5):1299-309. PubMed ID: 18438830
[TBL] [Abstract][Full Text] [Related]
16. Repair of bone erosions in rheumatoid arthritis treated with tumour necrosis factor inhibitors is based on bone apposition at the base of the erosion.
Finzel S; Rech J; Schmidt S; Engelke K; Englbrecht M; Stach C; Schett G
Ann Rheum Dis; 2011 Sep; 70(9):1587-93. PubMed ID: 21622765
[TBL] [Abstract][Full Text] [Related]
17. Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis.
Ebina K; Hirao M; Hashimoto J; Matsuoka H; Iwahashi T; Chijimatsu R; Etani Y; Okamura G; Miyama A; Yoshikawa H
Osteoporos Int; 2018 Jul; 29(7):1627-1636. PubMed ID: 29574517
[TBL] [Abstract][Full Text] [Related]
18. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
19. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis.
Sharp JT; Tsuji W; Ory P; Harper-Barek C; Wang H; Newmark R
Arthritis Care Res (Hoboken); 2010 Apr; 62(4):537-44. PubMed ID: 20391509
[TBL] [Abstract][Full Text] [Related]
20. Micro-structural bone changes in early rheumatoid arthritis persist over 1-year despite use of disease modifying anti-rheumatic drug therapy.
Feehan LM; Li LL; McKay HA
BMC Musculoskelet Disord; 2017 Dec; 18(1):521. PubMed ID: 29228959
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
